2C5V image
Entry Detail
PDB ID:
2C5V
Keywords:
Title:
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2005-11-02
Release Date:
2006-03-01
Method Details:
Experimental Method:
Resolution:
2.90 Å
R-Value Free:
0.28
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:CELL DIVISION PROTEIN KINASE 2
Chain IDs:A, C
Chain Length:298
Number of Molecules:2
Biological Source:HOMO SAPIENS
Polymer Type:polypeptide(L)
Description:CYCLIN A2
Chain IDs:B, D
Chain Length:259
Number of Molecules:2
Biological Source:HOMO SAPIENS
Polymer Type:polypeptide(L)
Description:ALA-ALA-ABA-ARG-SER-LEU-ILE-PFF-NH2
Chain IDs:E (auth: F), F (auth: H)
Chain Length:9
Number of Molecules:2
Biological Source:SYNTHETIC CONSTRUCT
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
ABA E ALA ALPHA-AMINOBUTYRIC ACID
PFF E PHE 4-FLUORO-L-PHENYLALANINE
Ligand Molecules
Primary Citation
Differential Binding of Inhibitors to Active and Inactive Cdk2 Provides Insights for Drug Design.
Chem.Biol. 13 201 ? (2006)
PMID: 16492568 DOI: 10.1016/J.CHEMBIOL.2005.11.011

Abstact

The cyclin-dependent kinases (CDKs) have been characterized in complex with a variety of inhibitors, but the majority of structures solved are in the inactive form. We have solved the structures of six inhibitors in both the monomeric CDK2 and binary CDK2/cyclinA complexes and demonstrate that significant differences in ligand binding occur depending on the activation state. The binding mode of two ligands in particular varies substantially in active and inactive CDK2. Furthermore, energetic analysis of CDK2/cyclin/inhibitors demonstrates that a good correlation exists between the in vitro potency and the calculated energies of interaction, but no such relationship exists for CDK2/inhibitor structures. These results confirm that monomeric CDK2 ligand complexes do not fully reflect active conformations, revealing significant implications for inhibitor design while also suggesting that the monomeric CDK2 conformation can be selectively inhibited.

Legend

Protein

Chemical

Disease